01475nas 2200457-a 450 99621403020331620230522213016.01543-4311(DE-599)ZDB2205933-7(OCoLC)51577430(CKB)111056645948150(CONSER)--2003212076(EXLCZ)9911105664594815020030205a20049999 --- aengur|||||||||||txtrdacontentcrdamediacrrdacarrierLanguage assessment quarterly[Mahwah, N.J.] Lawrence Erlbaum Associates, Inc.2004-[Philadelphia, PA] Taylor & Francis1 online resourceRefereed/Peer-reviewed1543-4303 LANG ASSESS QLANG. ASSESS. QLanguage and languagesAbility testingPeriodicalsLangage et languesTests d'aptitudePériodiquesLanguage and languagesAbility testingfast(OCoLC)fst00992155Periodicals.fastPeriodicals.lcgftLanguage and languagesAbility testingLangage et languesTests d'aptitudeLanguage and languagesAbility testing.400Lawrence Erlbaum Associates,JOURNAL996214030203316Language assessment quarterly2206060UNISA02567nam 2200409 450 991014156720332120240213154935.088-15-31408-3(CKB)2670000000361393(NjHacI)992670000000361393(EXLCZ)99267000000036139320240213d2013 uy 0itaur|||||||||||txtrdacontentcrdamediacrrdacarrierNuovi bisogni finanziari la risposta del microcredito /Antonio Andreoni, Marco Sassatelli, Giulia VichiBologna :Societa editrice il Mulino, Spa,2013.1 online resource (277 pages)Studi e ricerche (il Mulino) ;651Dedica -- Ringraziamenti -- Introduzione -- PARTE I. IL MICROCREDITO: AMBITI DI INTERVENTO E MODALITÀ DI OFFERTA -- Capitolo primo Bisogni finanziari e microcredito in Italia -- Capitolo secondo Il microcredito in Italia: modelli non bancari a confronto -- Capitolo terzo Le risposte tecniche dell'industria bancaria italiana -- PARTE II. DOMANDE DI MICROCREDITO E MODELLI DI RISPOSTA -- Capitolo quarto Le domande di microcredito: bisogni, mercati e prodotti -- Capitolo quinto Modelli contestuali di microcredito -- PARTE III. POLITICHE DEL MICROCREDITO -- Capitolo sesto Le politiche del microcredito -- Indice delle tabelle -- Indice delle figure -- Autori -- Riferimenti bibliografici.Mentre in Europa il settore del microcredito si consolida e viene da più parti promosso come una delle risposte alla crisi economica e finanziaria, sul versante italiano si registrano preoccupanti segni di ritardo. A quasi un decennio dalle prime sperimentazioni, infatti, il microcredito nel nostro paese sembra ancora intrappolato in una fase di avviamento. Oltre ad analizzare le ragioni di tale mancato decollo, il volume illustra una serie di modelli operativi, tecniche e strategie di risposta finalizzati al superamento dei limiti del settore in Italia, inquadrandoli all'interno di una agenda di politiche per il microcredito.Studi e ricerche (Società editrice Il mulino) ;651.Nuovi bisogni finanziariMicrofinanceMicrofinance.332Andreoni Antonio1859-1945,1592725Sassatelli MarcoVichi GiuliaNjHacINjHaclBOOK9910141567203321Nuovi bisogni finanziari3911534UNINA04856nam 2200637Ia 450 991083098580332120221226232417.01-280-74297-697866107429740-470-79050-40-470-98737-51-4051-7237-1(CKB)1000000000351286(EBL)284282(SSID)ssj0000151322(PQKBManifestationID)11146928(PQKBTitleCode)TC0000151322(PQKBWorkID)10317389(PQKB)11255893(MiAaPQ)EBC284282(OCoLC)181343640(EXLCZ)99100000000035128620040715d2005 fy 0engur|n|---|||||txtccrEvidence-based respiratory medicine[electronic resource] /edited by Peter Gibson ... [et al.]London BMJ20051 online resource (642 p.)Evidence-Based MedicineDescription based upon print version of record.0-7279-1605-X Includes bibliographical references and index.Evidence-based Respiratory Medicine; Contents; Contributors; Acknowledgement to Cochrane Library; 1. Practising evidence-based respiratory medicine; 1.1 Introduction; 1.2 Diagnostic strategies; 1.2.1 Presenting symptoms; 1.2.2 Lung function testing; 1.2.3 Chest radiographic and computerized tomography patterns; 1.2.4 Diagnostic strategies in pulmonary embolism: an evidence-based approach; 1.2.5 Screening for lung cancer; 1.3 Therapeutics: general issues; 1.3.1 Adherence and self-management; 1.3.2 Corticosteroid-induced osteoporosis; 1.3.3 Helping people to stop smoking; 2. Asthma2.1 Acute exacerbations2.2 Chronic therapy: B-agonists,short-acting,long-acting B2-agonists; 2.3 Inhaled corticosteroids in the treatment of asthma; 2.4 Anti-leukotrienes; 2.5 Asthma education; 2.6 Non-pharmacological and complementary interventions to manage asthma; 2.7 Difficult asthma; 2.8 Novel therapies in asthma: long-acting B2 -agonists/inhaled corticosteroids; 3. Chronic obstructive pulmonary disease; 3.1 Chronic obstructive pulmonary disease -acute exacerbations; 3.2 Anticholinergic bronchodilators in chronic obstructive pulmonary disease therapy3.3 Inhaled corticosteroids in chronic obstructive pulmonary disease3.4 Combination of inhaled corticosteroids and long-acting B2 -agonists in chronic obstructive pulmonary disease; 3.5 Systemic corticosteroids in stable chronic obstructive pulmonary disease; 3.6 Lung volume reduction; 4. Infection; 4.1 Bronchitis and sinusitis; 4.2 Community-acquired pneumonia; 4.3 Pulmonary tuberculosis; 4.4 Influenza: vaccination and treatment; 4.5 Bronchiectasis; 4.6 Adult cystic fibrosis; 4.7 Antibiotics in chronic obstructive pulmonary disease, bronchiectasis and cystic fibrosis5. Respiratory failure/sleep-disordered breathing5.1 Respiratory rehabilitation; 5.2 Non-invasive ventilation in acute respiratory failure; 5.3 Non-invasive positive pressure ventilation in stable patients with chronic obstructive pulmonary disease. What is the evidence?; 5.4 The treatment of the obstructive sleep apnoea-hypopnoea syndrome; 5.5 Long-term oxygen therapy for chronic respiratory failure in chronic obstructive pulmonary disease; 6. Diffuse lung disease/pleural disease/thromboembolism; 6.1 Diffuse lung disease; 6.1.1 The treatment of cryptogenic fibrosing alveolitis6.1.2 Evidence-based approach to the treatment of sarcoidosis6.1.3 Hypersensitivity pneumonitis; 6.2 Pleural disease; 6.3 Therapy of pulmonary thromboembolism: an evidence-based approach; 6.4 Pulmonary hypertension; IndexFirst major evidence-based text in adult respiratory medicineComprehensive, authoritative summary of the best treatments for the major respiratory diseasesCompiled by specialists from the Cochrane Airways Management GroupEasy-to-use format, with key clinical implications summarised in each chapterKept up-to-date online Compiled by specialists from the Cochrane Collaboration Airways Management Group, Evidence-based Respiratory Medicine is the first major evidence-based text in adult respiratory medicine. Providing a comprehensive summary of the best treatEvidence-Based MedicineRespiratory organsDiseasesEvidence-based medicineRespiratory organsDiseases.Evidence-based medicine.616.2/004644.84bclGibson PeterDr.990660MiAaPQMiAaPQMiAaPQBOOK9910830985803321Evidence-based respiratory medicine2266772UNINA01869nas 2200529-a 450 991014696010332120240912213021.0(OCoLC)60620294(CKB)111032812861440(CONSER)--2007266086(EXLCZ)9911103281286144020050614a19979999 --- -engur|||||||||||txtrdacontentcrdamediacrrdacarrierThe Quinnipiac probate law journal[Hamden, Conn.] [Quinnipiac College, School of Law]Refereed/Peer-reviewed1096-1054 Quinnipiac Prob. L.J.QUINNIPIAC PROBATE LAW JOURNAL, THEQUINNIPIAC PROBATE LAW JOURNALCONNECTICUT PROBATE LAW JOURNAL SEEProbate law and practiceConnecticutPeriodicalsProbate law and practiceConnecticutCasesTestamentsVérificationConnecticutPériodiquesTestamentsVérificationConnecticutJurisprudenceProbate law and practicefast(OCoLC)fst01077764Connecticutfasthttps://id.oclc.org/worldcat/entity/E39PBJkD9jxrm8YFj6Gy74HQv3Periodicals.fastTrials, litigation, etc.fastProbate law and practiceProbate law and practiceTestamentsVérificationTestamentsVérificationProbate law and practice.345.746/077347.460577Quinnipiac College.School of Law.National College of Probate Judges (U.S.)Connecticut Probate Assembly.JOURNAL9910146960103321The Quinnipiac probate law journal2267567UNINA